NCT00556959View on ClinicalTrials.gov

Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

high dose clonidine HCl sustained release

high dose clonidine HCl sustained release tablets for 8 weeks

DRUG

low dose clonidine HCl sustained release

low dose clonidine HCl sustained release tablets for 8 weeks

DRUG

placebo

placebo tablets for 8 weeks

Trial Locations (13)

27514

Chapel Hill

28209

Charlotte

32216

Jacksonville

32607

Gainesville

32806

Orlando

33161

Miami

48307

Rochester Hills

73103

Oklahoma City

73116

Oklahoma City

77007

Houston

77566

Lake Jackson

08021

Clementon

08043

Voorhees Township

Sponsors
All Listed Sponsors
lead

Addrenex Pharmaceuticals, Inc.

INDUSTRY

NCT00556959 - Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter